Dupilumab for Severe Eosinophilic Chronic Sinusitis

Overseen By Thanh Q Tran, MPH

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: University of South Florida

Must be taking: Intranasal corticosteroids

Must not be taking: Biologics, Immunosuppressants, Monoclonal antibodies, others

Disqualifiers: Asthma, Cancer, Immunodeficiency, others

Prior Safety Data This treatment has passed at least one previous human trial

Breakthrough Therapy This drug has been fast-tracked for approval by the FDA given its high promise

Approved in 2 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

Duration: 24 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests dupilumab, a medication, to determine its effectiveness for people with severe eosinophilic chronic sinusitis without nasal polyps. This condition causes painful and persistent sinus issues that do not improve with standard nasal sprays. Participants should experience symptoms like nasal blockage, nasal discharge, or facial pain and have a specific type of sinusitis involving multiple sinuses. The trial compares dupilumab with a placebo (a non-active treatment) to assess effectiveness. For those with eosinophilic sinusitis affecting daily life who have not found relief with other treatments, this trial may be suitable. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Will I have to stop taking my current medications?

The trial requires that you stop taking certain medications before joining. For example, you must not have taken biologic therapy or systemic immunosuppressants within 2 months before screening, and you must have been on a continuous treatment with leukotriene antagonists for at least 30 days prior to screening. Please check with the trial team for specific guidance on your current medications.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that dupilumab has been tested for safety in various conditions. Some studies found that people taking dupilumab experienced more common colds and mild skin reactions at the injection site compared to those taking a placebo. Another study found that dupilumab was generally safe when used with other treatments for certain diseases. While these studies provide some safety information, clinical trials like this one help determine how safe and effective a treatment is for different conditions. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising?

Unlike the standard treatments for severe eosinophilic chronic sinusitis, which often involve steroids and nasal sprays, Dupilumab offers a novel approach by targeting the interleukin-4 receptor alpha. This mechanism disrupts the signaling of certain proteins that drive inflammation, providing a more precise attack on the root causes of the condition. Researchers are excited because this could mean fewer side effects and potentially better long-term outcomes compared to traditional therapies.

What evidence suggests that dupilumab might be an effective treatment for severe eosinophilic chronic sinusitis?

Research has shown that dupilumab effectively treats chronic rhinosinusitis with nasal polyps, similar to eosinophilic chronic sinusitis. Studies have found that patients using dupilumab experienced significant improvements in symptoms and sinus health, such as reduced nasal blockage and better sinus scan results. Dupilumab blocks certain proteins that cause inflammation, reducing sinus swelling and related symptoms. In this trial, participants will receive either dupilumab or a placebo to evaluate its potential use in treating severe eosinophilic chronic sinusitis. ^{5 6 7 8 9}

Who Is on the Research Team?

Seong Cho, MD

Principal Investigator

University of South Florida

Are You a Good Fit for This Trial?

Adults with severe eosinophilic chronic sinusitis without nasal polyps, who haven't improved after at least 8 weeks of standard nasal corticosteroid treatment. Participants must have a high Lund-Mackay CT score (≥10), significant blood eosinophils (≥200), and experience symptoms like nasal blockage or loss of smell. Excluded are those with certain other conditions, recent infections requiring antibiotics, immunodeficiencies, cancer history within 5 years, drug abuse in the past year, pregnancy, breastfeeding or participation in another clinical trial.

Inclusion Criteria

LMK-CT score ≥ 10 (out of maximum of 24) at screening

Age 18 or older

The person has bilateral sinusitis, meaning that they have infection in both of their sinuses, and it has not been cured by using a corticosteroid treatment for at least 8 weeks.

Exclusion Criteria

Patients with conditions/concomitant diseases making them non-evaluable at screening or for the primary efficacy endpoint such as: Antrochoanal polyps, Nasal septal deviation that would occlude at least one nostril, Acute sinusitis, nasal infection or upper respiratory infection at screening, Ongoing rhinitis medicamentosa, Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis), Young's syndrome, Kartagener's syndrome or other dyskinetic ciliary syndromes, concomitant cystic fibrosis, Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis, With co-morbid asthma are excluded if forced expiratory volume (FEV1) is 50% (of predicted normal) or less, With known active bacterial, viral, fungal, mycobacterial infection, or other infection or any major episode of infection that required hospitalization or treatment with IV antibiotics within 30 days of screening or during screening or oral antibiotics within 14 days prior to screening. Fungal infection of nail beds is allowed, Have human immunodeficiency virus/acquired immune deficiency syndrome, Have acute or chronic hepatitis B/hepatitis C infection, History of an opportunistic infection (eg, pneumocystis carinii, cryptococcal meningitis, progressive multifocal leukoencephalopathy) or serious bacterial, viral, or fungal infections (eg, disseminated herpes simplex, disseminated herpes zoster) and requiring IV medication(s) ≤ 3 weeks prior to randomization, History of or currently active primary or secondary immunodeficiency, History of cancer within the last 5 years, including solid tumors and hematological malignancies (except basal cell and in situ squamous cell carcinomas of the skin that have been excised and resolved) or colonic mucosal dysplasia, History of lymphoproliferative disorder, lymphoma, leukemia, myeloproliferative disorder, or multiple myeloma, History of alcohol or drug abuse within 1 year prior to randomization, Receipt of live vaccine within 4 weeks prior to randomization, Pregnant or breastfeeding, Participation in another clinical study or treatment with an investigational drug or device, Serious or active medical or psychiatric condition which, in the opinion of the Investigator, may interfere with treatment, assessment, or compliance with the protocol

You have received an experimental monoclonal antibody within the past 6 months or within five times its half-life if its duration is unknown.

You have previously participated in a clinical trial for a medication called dupilumab.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Dupilumab 300 mg every other week for 24 weeks

24 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Dupilumab

Trial Overview The study is testing Dupilumab's effectiveness for patients with severe eosinophilic chronic sinusitis who don't respond to usual treatments. It involves comparing Dupilumab injections against a placebo to see if it can reduce disease severity as shown by CT scans and symptom scores.

How Is the Trial Designed?

Group I: Active drug Active Control 1 Intervention

Dupilumab 300 mg every other week for 24 weeks

Group II: Placebo Placebo Group 1 Intervention

Placebo

Dupilumab is already approved in United States, European Union for the following indications:

Approved in United States as Dupixent for:

• Atopic dermatitis
• Asthma
• Chronic rhinosinusitis with nasal polyps
• Eosinophilic esophagitis

Approved in European Union as Dupixent for:

• Atopic dermatitis
• Asthma
• Chronic rhinosinusitis with nasal polyps
• Eosinophilic esophagitis

Who Is Running the Clinical Trial?

University of South Florida

Lead Sponsor

Trials

433

Recruited

198,000+

Published Research Related to This Trial

In a study involving 724 patients with severe chronic rhinosinusitis with nasal polyps, dupilumab significantly improved symptoms of nasal congestion, loss of smell, and rhinorrhoea compared to placebo, with improvements seen as early as Week 2 and continuing through Week 52.

A higher proportion of patients treated with dupilumab reported a reduction from moderate-to-severe symptoms to no-to-mild symptoms at multiple time points, indicating its efficacy in managing this condition regardless of prior surgery or coexisting asthma.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps. Gevaert, P., Lee, SE., Settipane, RA., et al.[2023]

In a study of 130 patients treated with dupilumab for severe chronic rhinosinusitis with nasal polyps over 18 months, there was a significant reduction in nasal polyposis and improvement in symptoms and quality of life.

The treatment was associated with a transient increase in blood eosinophils and a gradual decrease in total IgE levels, indicating potential changes in immune response, although IgG and IgA levels remained within normal ranges.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Dupilumab's Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life. Loperfido, A., Ciofalo, A., Cavaliere, C., et al.[2023]

Dupilumab is an effective treatment for chronic rhinosinusitis with polyposis (CRSwNP), showing significant improvements in patients' subjective disease burden and objective measures, regardless of specific disease characteristics like aspirin exacerbated respiratory disease (AERD) or elevated eosinophil levels.

In a study of 75 patients, dupilumab therapy was reported to be more effective than functional endoscopic sinus surgery (FESS) in certain cases, indicating that some patients may benefit more from dupilumab than from surgical intervention.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study. Bertlich, M., Freytag, S., Dombrowski, T., et al.[2023]

In a study of 66 patients with chronic rhinosinusitis with nasal polyps (CRSwNP), dupilumab significantly reduced symptoms and nasal polyp scores after 6 and 12 months, indicating its effectiveness as a treatment.

The safety profile of dupilumab was favorable, with only 12.7% of patients experiencing injection site reactions and 11.1% having transient hypereosinophilia, suggesting it is a safe option for managing CRSwNP.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care. Galletti, C., Barbieri, MA., Ciodaro, F., et al.[2023]

Dupilumab significantly improved symptoms of chronic rhinosinusitis with nasal polyps (CRSwNP) in patients regardless of their surgical history, demonstrating its efficacy across different subgroups based on prior surgeries and time since last surgery.

Patients who had undergone surgery more recently (within <3 years) experienced greater improvements in nasal polyp scores and other measures compared to those who had surgery longer ago, while the safety profile of dupilumab remained consistent with previous findings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps. Hopkins, C., Wagenmann, M., Bachert, C., et al.[2021]

Dupilumab, a monoclonal antibody used to treat conditions like asthma and atopic dermatitis, can cause hypereosinophilia (high eosinophil levels) as a potential adverse effect, which poses a challenge for clinicians.

An algorithm has been proposed to help manage dupilumab-induced hypereosinophilia, allowing for proper investigation of related health issues while minimizing unnecessary discontinuation of the medication.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. Caminati, M., Olivieri, B., Dama, A., et al.[2022]

Dupilumab significantly improved symptoms and objective measures of chronic rhinosinusitis with nasal polyps (CRSwNP) in patients, regardless of whether they also had allergic rhinitis, based on a pooled analysis of 724 patients from two phase III studies.

The treatment also reduced the need for systemic corticosteroids and sinonasal surgery, demonstrating its efficacy and safety profile, which was consistent across patients with and without allergic rhinitis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis. Peters, AT., Wagenmann, M., Bernstein, JA., et al.[2023]

Citations

1. clinicaltrials.gov clinicaltrials.gov/study/NCT02912468

NCT02912468 | A Controlled Clinical Study of Dupilumab ... Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results ...

2. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/40870516/

Efficacy of Dupilumab in Patients with Chronic ... Efficacy of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps and Eosinophilic Otitis Media: A Six-Month Observational Study.

3. clinicaltrials.gov clinicaltrials.gov/study/NCT02898454

NCT02898454 | Controlled Clinical Study of Dupilumab in ... Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results ...

4. ncbi.nlm.nih.gov ncbi.nlm.nih.gov/books/NBK596600/

Clinical Review - Dupilumab (Dupixent) - NCBI Bookshelf - NIH The primary outcome was the annualized rate of severe exacerbations, while the key secondary outcome was pulmonary function measurement (i.e., change from ...

5. dupixenthcp.com dupixenthcp.com/crswnp/efficacy/safety-data-and-design

safety data and study designs in adults Review DUPIXENT® (dupilumab) demonstrated safety profile and clinical trial information for inadequately controlled chronic rhinosinusitis with nasal polyps ...

6. clinicaltrials.gov clinicaltrials.gov/study/NCT02277769

NCT02277769 | Study of Dupilumab (REGN668/ ... This is a randomized, double-blind, placebo-controlled, parallel-group study to confirm the efficacy and safety of Dupilumab monotherapy in adults with moderate ...

7. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC9574251/

Dupilumab efficacy and safety in patients with moderate to ... Compared to the placebo, dupilumab revealed a significantly higher incidence of upper respiratory tract infections (URTI), injection-site reaction, and ...

8. clinicaltrials.gov clinicaltrials.gov/study/NCT02260986

NCT02260986 | Study to Assess the Efficacy and Long- ... The primary objective of the study was to demonstrate the efficacy of Dupilumab administered concomitantly with topical corticosteroid (TCS) through Week 16 ...

9. annallergy.org annallergy.org/article/S1081-1206(25)00203-0/fulltext

Patient outcomes and safety of combination biologic ... Combination biologic therapy with dupilumab is well-tolerated in select patients, suggesting promising efficacy in addressing comorbid conditions, refractory ...